Hong Kong
· Delayed Price · Currency is HKD Shanghai Henlius Biotech Company Description
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.
It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer.
The company also develops : HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma and limited-stage small cell lung cancer.
HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma.
The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania.
The company was founded in 2010 and is headquartered in Shanghai, China.
| Country | China |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,515 |
| CEO | Jun Zhu |
Contact Details
Address: Building B8 Shanghai, 200233 China | |
| Phone | 86 21 3339 5800 |
| Website | henlius.com |
Stock Details
| Ticker Symbol | 2696 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100003N76 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jun Zhu | Chief Executive Officer and Executive Director |
| Huang Wei | President |
| Dr. Shi-Kau Liu | Co-founder and Head of Strategy Advisory Committee |
| Dr. Wei-Dong Jiang | Co-Founder and Co-Head of Innovative Advisory Committee |
| Yingbo Mao | Vice President and Chief Financial Officer |
| Dr. Jijun Yuan | Chief Scientific Officer |
| Miaojie Chen | Vice President of Legal and Compliance Department |
| Yan Wang | Deputy GM of Public Relations and Joint Company Secretary |
| Wallis Zeng | Vice President of Sales and Oncology Business Unit |
| Junhua Li | Senior Vice President and Chief Human Resources Officer |